ClearPoint Neuro, Inc. (CLPT): Price and Financial Metrics


ClearPoint Neuro, Inc. (CLPT): $10.94

0.50 (+4.79%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

CLPT POWR Grades


  • CLPT scores best on the Quality dimension, with a Quality rank ahead of 33.78% of US stocks.
  • The strongest trend for CLPT is in Momentum, which has been heading down over the past 179 days.
  • CLPT's current lowest rank is in the Momentum metric (where it is better than 16.1% of US stocks).

CLPT Stock Summary

  • With a price/sales ratio of 14.69, ClearPoint Neuro Inc has a higher such ratio than 90.29% of stocks in our set.
  • With a year-over-year growth in debt of -49.07%, ClearPoint Neuro Inc's debt growth rate surpasses only 7.73% of about US stocks.
  • Over the past twelve months, CLPT has reported earnings growth of 151.72%, putting it ahead of 86.89% of US stocks in our set.
  • If you're looking for stocks that are quantitatively similar to ClearPoint Neuro Inc, a group of peers worth examining would be LMNL, NATI, EYPT, VNDA, and WB.
  • CLPT's SEC filings can be seen here. And to visit ClearPoint Neuro Inc's official web site, go to www.clearpointneuro.com.

CLPT Valuation Summary

  • In comparison to the median Healthcare stock, CLPT's price/earnings ratio is 223.84% lower, now standing at -45.2.
  • Over the past 113 months, CLPT's EV/EBIT ratio has gone down 39.6.
  • Over the past 113 months, CLPT's price/sales ratio has gone up 20.9.

Below are key valuation metrics over time for CLPT.

Stock Date P/S P/B P/E EV/EBIT
CLPT 2021-08-31 28.8 8.8 -45.2 -45.6
CLPT 2021-08-30 27.7 8.5 -43.6 -43.9
CLPT 2021-08-27 28.1 8.6 -44.2 -44.6
CLPT 2021-08-26 26.7 8.2 -41.9 -42.0
CLPT 2021-08-25 27.2 8.3 -42.8 -43.0
CLPT 2021-08-24 27.3 8.4 -42.9 -43.1

CLPT Growth Metrics

    The 5 year revenue growth rate now stands at 138.25%.
  • Its 3 year net cashflow from operations growth rate is now at 55.97%.
  • Its year over year cash and equivalents growth rate is now at 282.05%.
Over the past 34 months, CLPT's revenue has gone up $8,096,583.

The table below shows CLPT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 16.299 -12.697 -14.41
2021-09-30 15.73344 -11.547 -11.8429
2021-06-30 14.67863 -9.617486 -9.347127
2021-03-31 13.74341 -7.607604 -7.265175
2020-12-31 12.829 -7.807 -6.782
2020-09-30 12.32312 -5.870809 -6.845807

CLPT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CLPT has a Quality Grade of C, ranking ahead of 36.69% of graded US stocks.
  • CLPT's asset turnover comes in at 0.297 -- ranking 130th of 186 Medical Equipment stocks.
  • ANGO, IVC, and MLSS are the stocks whose asset turnover ratios are most correlated with CLPT.

The table below shows CLPT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.297 0.680 -0.308
2021-03-31 0.370 0.694 -0.245
2020-12-31 0.524 0.711 -0.240
2020-09-30 0.613 0.740 -0.337
2020-06-30 0.652 0.704 -0.416
2020-03-31 0.763 0.674 -0.596

CLPT Price Target

For more insight on analysts targets of CLPT, see our CLPT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $32.00 Average Broker Recommendation 1.5 (Moderate Buy)

CLPT Stock Price Chart Interactive Chart >

Price chart for CLPT

CLPT Price/Volume Stats

Current price $10.94 52-week high $22.80
Prev. close $10.44 52-week low $7.00
Day low $10.39 Volume 135,200
Day high $11.23 Avg. volume 223,709
50-day MA $9.59 Dividend yield N/A
200-day MA $12.64 Market Cap 259.37M

ClearPoint Neuro, Inc. (CLPT) Company Bio


ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system, a neuro-navigation system designed for insertion of catheters, electrodes, and laser fibers to treat various neurological diseases and conditions, as well as for performing biopsies. In addition, the company's product pipeline includes ClearTrace system, a product candidate designed to allow catheter-based minimally invasive procedures in the heart to be performed in an MRI suite. The company has a license agreements with The Johns Hopkins University; development agreement with Mayo Clinic to design and develop MRI-guided therapies for stroke; and a collaborative license and co-development agreement with Clinical Laserthermia Systems AB. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was founded in 1998 and is headquartered in Irvine, California.


CLPT Latest News Stream


Event/Time News Detail
Loading, please wait...

CLPT Latest Social Stream


Loading social stream, please wait...

View Full CLPT Social Stream

Latest CLPT News From Around the Web

Below are the latest news stories about ClearPoint Neuro Inc that investors may wish to consider to help them evaluate CLPT as an investment opportunity.

ClearPoint Neuro: Underlying Growth Potential Concealed By COVID

This article is contributed by Jun Hao from our Superstocks Seekers team. [To receive real-time notifications of our latest updates/articles, click the "Follow" button on the left of your screen.] Overview ClearPoint Neuro (CLPT) is a neurological platform company that allows neurosurgeons to perform minimally invasive procedures for the most...

Superstocks Seekers on Seeking Alpha | January 14, 2022

Adirondack Trust Co Buys Vanguard Russell 2000 Index Fund, Ford Motor Co, Arco Platform, Sells ...

Saratoga Springs, NY, based Investment company Adirondack Trust Co (Current Portfolio) buys Vanguard Russell 2000 Index Fund, Ford Motor Co, Arco Platform, Kiniksa Pharmaceuticals, TransMedics Group Inc, sells Vanguard Russell 3000 Index Fund, Vanguard Total International Stock, AT&T Inc, Eli Lilly and Co, Vanguard FTSE Developed Markets ETF during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Adirondack Trust Co.

Yahoo | January 13, 2022

ClearPoint Neuro to Participate at the H.C. Wainwright BIOCONNECT Virtual Conference

SOLANA BEACH, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, announced today that its management will participate at the H.C. Wainwright BIOCONNECT Virtual Conference. A pre-recorded company presentation will be available on the conference website beginning at 7 a.m. ET / 4 a.m. PT on January 10, 2022. About ClearPoint Neuro ClearPoint Neuro’s mission is to

Yahoo | January 5, 2022

Royce Value Trust, Inc. Buys Calix Inc, MaxCyte Inc, Dutch Bros Inc, Sells EQT Corp, ...

Investment company Royce Value Trust, Inc. (Current Portfolio) buys Calix Inc, MaxCyte Inc, Dutch Bros Inc, Eagle Materials Inc, Scientific Games Corp, sells EQT Corp, SmileDirectClub Inc, , Hilton Grand Vacations Inc, Kulicke & Soffa Industries Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Royce Value Trust, Inc..

Yahoo | December 17, 2021

ClearPoint Neuro (NASDAQ:CLPT) shareholders are still up 635% over 3 years despite pulling back 13% in the past week

It might be of some concern to shareholders to see the ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) share price down 20% in...

Yahoo | November 20, 2021

Read More 'CLPT' Stories Here

CLPT Price Returns

1-mo 23.62%
3-mo 26.18%
6-mo -19.91%
1-year -40.61%
3-year 240.81%
5-year 241.88%
YTD -2.50%
2021 -29.39%
2020 231.04%
2019 205.73%
2018 -42.91%
2017 -19.12%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7804 seconds.